NCT05661552View on ClinicalTrials.gov

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

PHASE4CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Interventions
DRUG

Evolocumab 140 MG/ML

Randomly assigned Evolocumab + rosuvastatin + ezetimibe versus rosuvastatin + ezetimibe

DRUG

Rosuvastatin 5mg

Rosuvastatin 5mg will be assigned to all participants

DRUG

Ezetimibe 10mg

Ezetimibe 10mg will be assigned to all participants

Trial Locations (1)

16995

Yongcheol Kim, Yongin

Sponsors
All Listed Sponsors
collaborator

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

lead

Yonsei University

OTHER

NCT05661552 - Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI | Biotech Hunter | Biotech Hunter